Yellow Fever Vaccine Market Trends and Forecast
The future of the global yellow fever vaccine market looks promising with opportunities in the routine immunization and traveler markets. The global yellow fever vaccine market is expected to grow with a CAGR of 4.2% from 2025 to 2031. The major drivers for this market are the rising incidences of yellow fever outbreaks and the increasing travel & migration.
• Lucintel forecasts that, within the type category, institutional contribution is expected to witness higher growth over the forecast period.
• Within the application category, routine immunization is expected to witness higher growth.
• In terms of region, North America is expected to witness the highest growth over the forecast period.
Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.
Emerging Trends in the Yellow Fever Vaccine Market
The yellow fever vaccine market is experiencing a number of emerging trends aimed at enhancing vaccine safety, supply security, and accessibility.
• Alternative Vaccine Platform Development: One of the most important upcoming trends is research and development of alternative yellow fever vaccine platforms to the conventional live-attenuated vaccine. This entails the discovery of inactivated vaccines, subunit vaccines, and viral-vectored vaccines. These platforms are intended to overcome concerns regarding the safety of the live vaccine and potentially provide better scalability for production during outbreaks.
• Emphasize Single-Dose Vaccine Immunogenicity and Duration of Protection: Although lifetime immunity from the present live-attenuated vaccine is assured, studies persist in tracking long-term single-dose effectiveness and defining the immunologic correlates of immunity. Ongoing surveillance provides assurance for the present immunization practice and guides future vaccine development.
• Strengthening Supply Chain Resilience and Response to Outbreaks: Provision of a sound and responsive supply chain for the yellow fever vaccine, especially amidst outbreaks, is a new direction. This incorporates enhancing manufacturing strength, creating stocks in buffer storage, and developing distribution channels so that vaccines may be quickly transported to affected regions and averts widespread disease.
• Developments in Yellow Fever Diagnostic Tools: Although not a vaccine per se, developments in rapid and reliable diagnostic tools for yellow fever are essential to facilitate early detection and focused vaccination campaigns during outbreaks. Better diagnostics can enable rapid identification of infected areas and help streamline vaccine distribution strategies.
• Incorporation of Yellow Fever Vaccination into Comprehensive Travel Health Services: There is a movement towards incorporating yellow fever vaccination into comprehensive pre-travel health consultations. This way, travelers are provided with proper risk assessment, vaccination recommendation, and other preventive interventions as per their destination and personal health status.
These trends are restructuring the yellow fever vaccine market by propelling innovation towards safer, more scalable vaccine choices, enhancing faith in existing single-dose strategy, solidifying the capability to respond efficiently to outbreaks, enhancing diagnostic abilities for targeted responses, and validating vaccination as an integral part of holistic travel health management.
Recent Development in the Yellow Fever Vaccine Market
The yellow fever vaccine market is witnessing advancements geared towards securing global health and enhancing vaccine access and safety.
• Ongoing Dependence on the 17D Live-Attenuated Vaccine: In spite of continued research, the 17D strain-based live-attenuated vaccine is still the foundation of yellow fever prevention, showing long-term effectiveness and a robust safety profile in the majority of people. Recent advancements focus on optimizing its manufacture and delivery.
• WHO Efforts toward Supply Assurance and Outbreak Response: WHO continues to perform a key role in coordinating global yellow fever vaccine supply, especially in the face of outbreaks. Current developments have involved efforts at establishing stockpiles and maintaining fair access to vaccines in impacted areas.
• Fractional Dosing Research During Outbreaks: Due to vaccine shortages during mass outbreaks, research has been conducted on the efficacy of fractional doses of the 17D vaccine. Recent findings offer additional evidence in favor of fractional dosing as a temporary measure to stretch vaccine supply during crises.
• Continuous surveillance of Rare Adverse Events: Strong pharmacovigilance systems continue to track rare serious adverse events in relation to the yellow fever vaccine, including viscerotropic and neurotropic disease. Some recent advances include increased surveillance and research to have a better comprehension of risk factors and enhance patient safety.
• Slow Development of Alternative Vaccine Platforms: Although development in alternative vaccine platforms has been ongoing, no recent approvals of non-live-attenuated yellow fever vaccines have been granted for mass use. Recent advances in the field have mainly been preclinical and initial-stage clinical trials.
These advances are affecting the yellow fever vaccine market by reaffirming the value of the current vaccine, enhancing global response capacity during outbreaks, offering solutions to vaccine shortage management, ensuring continued safety surveillance, and emphasizing the ongoing need for successful alternative vaccine development.
Strategic Growth Opportunities in the Yellow Fever Vaccine Market
The yellow fever vaccine market, being comparatively mature, offers strategic growth opportunities through fulfilling unmet needs and capitalizing on changing global health priorities.
• Enhancing Routine Immunization Programs in Endemic Nations: One of the most important growth opportunities is to strengthen and expand routine yellow fever immunization programs in endemic nations. This involves additional funding, better healthcare infrastructure, and increased community participation to achieve high vaccination coverage and avoid outbreaks.
• Creating More Thermostable Vaccines for Resource-Constrained Settings: The present live-attenuated vaccine needs a rigorous cold chain, which is logistically challenging in most endemic countries. Creating more thermostable formulations that are resistant to heat would greatly enhance vaccine accessibility and coverage in resource-constrained settings.
• Investigating Combination Vaccines Containing Yellow Fever: Incorporating yellow fever antigens into combination vaccines with other travel-associated or childhood vaccines may simplify immunization schedules, enhance compliance, and possibly increase the coverage of yellow fever protection.
• Progress in Research and Development of Safer Vaccines for Contraindicated Persons: There is an opportunity for growth in the development of safe and effective yellow fever vaccines for contraindicated persons, like immunocompromised persons and infants under six months. Other platforms may solve this unmet medical need.
• Harnessing Digital Health Technologies for Tracking Vaccines and Surveillance: The use of digital health technologies for tracking vaccination history, monitoring coverage levels, and enhancing surveillance for yellow fever cases and outbreaks can enhance the effectiveness of vaccination efforts and public health responses, offering possibilities for more effective deployment of vaccines.
These strategic opportunities for growth emphasize the potential for the yellow fever vaccine market to increase its reach by enhancing routine immunization in endemic countries, creating more affordable formulations, compatibility with other vaccines, serving the needs of contraindicated populations, and using technology for enhanced tracking and surveillance.
Yellow Fever Vaccine Market Driver and Challenges
The yellow fever vaccine market is driven by the ongoing threat of outbreaks and the need to travel internationally, facing challenges associated with supply constraints and the inherent limitations of the available vaccine.
The factors responsible for driving the yellow fever vaccine market include:
1. Threat of Yellow Fever Outbreaks in Endemic Areas: The constant threat of yellow fever outbreaks in tropical areas of Africa and South America is the key driver for vaccination and market demand.
2. International Travel Guidelines: Most countries demand yellow fever vaccination proof from travelers coming from or passing through endemic regions, generating a regular demand for the vaccine.
3. WHO Recommendations and Guidelines: The World Health Organization (WHO) has an important role in suggesting yellow fever vaccination for exposed individuals and travelers and shaping national immunization policies and market demand.
4. Lifelong Immunity after a Single Dose: The proven efficacy of a single dose of the live-attenuated vaccine in conferring lifelong immunity maintains its usage and demand.
5. Rising Awareness of Health Risks of Travel: Rising awareness of health risks when traveling abroad supports the demand for preventive interventions, such as yellow fever vaccination.
Challenges in the yellow fever vaccine market are:
1. Supply Limitations During Outbreaks: The process of manufacturing the present live-attenuated vaccine is complicated and time-consuming, and thus there are chances of supply shortages during outbreaks when demand is high.
2. Serious but Uncommon Adverse Events: The live-attenuated vaccine is associated with a risk, though uncommon, of serious adverse events like viscerotropic and neurotropic disease, which may discourage vaccination in certain persons.
3. Cold Chain Requirements: The requirement for rigorous cold chain preservation of the live-attenuated vaccine presents tremendous logistical challenges, especially in resource-scarce endemic areas.
In short, the yellow fever vaccine market is influenced by the threat of outbreaks, travel requirements across borders, WHO guidelines, and the long-term immunity of the vaccine. It is, however, hampered by supply shortages in emergency situations, the possibility of adverse effects with very low frequency, and the logistics of maintaining the cold chain.
List of Yellow Fever Vaccine Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies yellow fever vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the yellow fever vaccine companies profiled in this report include-
• Sanofi Pasteur
• Bio-Manguinhos
• FSUE Chumakov
• Institut Pasteur de Dakar
Yellow Fever Vaccine Market by Segment
The study includes a forecast for the global yellow fever vaccine market by type, application, and region.
Yellow Fever Vaccine Market by Type [Value from 2019 to 2031]:
• Institonal Contributions
• Private Purchase
• Others
Yellow Fever Vaccine Market by Application [Value from 2019 to 2031]:
• Routine Immunization
• Travelers
• Other
Yellow Fever Vaccine Market by Region [Value from 2019 to 2031]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Yellow Fever Vaccine Market
Recent advancements in the yellow fever vaccine market are influenced by the persistent risk of outbreak in endemic areas and growing levels of international travel. The established live-attenuated vaccine gives lifelong protection but has challenges around supply shortages in outbreak periods and possible rare side effects. Alternative vaccine platforms like inactivated vaccines and recombinant technologies are being investigated in research to increase safety and scalability. Regulatory agencies and global health institutions have a pivotal role to play in providing vaccine quality and availability throughout the United States, China, Germany, India, and Japan, with implications on market trends and future orientations.
• United States: Demand in the US yellow fever vaccine market is largely dominated by demand among travelers to endemic areas. The latest developments have involved continuous observation of vaccine supply and advice by the Centers for Disease Control and Prevention (CDC) on vaccine guidelines. Areas of research concentrate on rare adverse effects and researching alternative vaccines in patients with contraindications to the live vaccine.
• China: The Chinese yellow fever vaccine market is relatively modest, being largely driven by outbound travel to endemic countries in Africa and South America. Recent trends include strict regulatory control over imported vaccines and attempts to maintain adequate supply for travelers. Domestic production of yellow fever vaccine is limited, leaving the country dependent on international suppliers.
• Germany: GermanyÄX%$%Xs market for yellow fever vaccine is mainly aimed at immunizing travelers. Developments in recent times include compliance with European Union (EU) standards for vaccine quality and safety. Healthcare professionals provide pre-travel consultations and administer the vaccine according to international health regulations. Domestic production is minimal, and the market depends on imports.
• India: India is not endemic for yellow fever, and demand in the vaccine market comes from requirements for compliance with international health rules by travelers. Developments of late are that WHO-prequalified vaccines have been made available at specified centers. Emphasis lies in the accessibility of individuals who are to travel to risk areas, and limited domestic need over travel requisites.
• Japan: The Japanese yellow fever vaccine market serves primarily international travelers. Recent trends include the offering of vaccination services at authorized quarantine stations and travel clinics. International health regulations are followed by Japan for yellow fever immunization to enter some countries. Domestic production is minimal, and the market depends on imported vaccines.
Features of the Global Yellow Fever Vaccine Market
Market Size Estimates: Yellow fever vaccine market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Yellow fever vaccine market size by type, application, and region in terms of value ($B).
Regional Analysis: Yellow fever vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the yellow fever vaccine market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the yellow fever vaccine market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for yellow fever vaccine market?
Answer: The global yellow fever vaccine market is expected to grow with a CAGR of 4.2% from 2025 to 2031.
Q2. What are the major drivers influencing the growth of the yellow fever vaccine market?
Answer: The major drivers for this market are the rising incidences of yellow fever outbreaks and the increasing travel & migration.
Q3. What are the major segments for yellow fever vaccine market?
Answer: The future of the yellow fever vaccine market looks promising with opportunities in the routine immunization and traveler markets.
Q4. Who are the key yellow fever vaccine market companies?
Answer: Some of the key yellow fever vaccine companies are as follows:
• Sanofi Pasteur
• Bio-Manguinhos
• FSUE Chumakov
• Institut Pasteur de Dakar
Q5. Which yellow fever vaccine market segment will be the largest in future?
Answer: Lucintel forecasts that, within the type category, institutional contribution is expected to witness higher growth over the forecast period.
Q6. In yellow fever vaccine market, which region is expected to be the largest in next 5 years?
Answer: In terms of region, North America is expected to witness the highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the yellow fever vaccine market by type (institonal contributions, private purchase, and others), application (routine immunization, travelers, and other), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Yellow Fever Vaccine Market, Yellow Fever Vaccine Market Size, Yellow Fever Vaccine Market Growth, Yellow Fever Vaccine Market Analysis, Yellow Fever Vaccine Market Report, Yellow Fever Vaccine Market Share, Yellow Fever Vaccine Market Trends, Yellow Fever Vaccine Market Forecast, Yellow Fever Vaccine Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.